Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
StemoniX logo — Pre-plated, human iPSC-derived microOrgans for toxicology an...

StemoniX

Pre-plated, human iPSC-derived microOrgans for toxicology and drug discovery research

Founded 2014 United States Maple Grove, United States 1 employees Convertible Note Total: $33.21M Biotechnology, Health Care

General Information

Company Name StemoniX
Founded Year 2014
Location United States Maple Grove, United States +1
Employees 1
Industries Biotechnology, Health Care
Funding Stage Convertible Note
Social

Get notified when StemoniX moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About StemoniX

StemoniX is a biotechnology startup based in the United States, founded in 2014, focusing on accelerating the discovery of new medicines through the development and scalable manufacture of human induced pluripotent stem (iPS) cell-derived cardiac and neural platforms for drug discovery and development (last investment: Convertible Note investment at 25 August 2020, investors: For Good Ventures). The company's mission is to improve cell-based assay outcomes by offering physiologically-relevant, structured human cells. Their products, microHeart® and microBrain®, provide researchers with high-density plate formats of cardiac and neural cells, pre-plated and ready for assay use soon after delivery. StemoniX collaborates with drug discovery organizations to test compounds using their in-house screening capabilities and create new cell-based models, contributing to the operationalization of human iPS cells at large scale for high throughput screening. The company's cutting-edge iPSC technologies aim to bring the most promising medicines to patients, and they welcome inquiries about how their products and services can accelerate discoveries ([email protected]). Overall, StemoniX's focus on developing predictive, accurate, and consistent human models aligns with the growing demand for more effective drug discovery and development tools in the biotechnology and healthcare industries (industries: Biotechnology, Health Care). Through its innovative approach and collaborations, StemoniX presents a potential opportunity for investors looking to support advancements in drug discovery and improvement in healthcare outcomes.

Taxonomy: Stem Cell Technologies, Drug Discovery, Personalized Medicine, iPS Cells, Cardiomyocytes, Neurons, Astrocytes, High Throughput Screening, In Vitro Assay Development, Disease Modeling, Hazard Identification, Cell-based Assays, Toxicology Research, Regenerative Medicine

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Convertible Note •••••• 1
Investor
25 Aug 2020
Venture Round •••••• 1
Investor
15 May 2020
Venture Round •••••• - 04 Oct 2019
Series B •••••• 5
Investor Investor Investor Investor
•••• •••• 		28 Feb 2019
Venture Round •••••• - 22 Aug 2018

View All 11 Funding Rounds

StemoniX Alternatives & Competitors

StemoniX vs
Altis Biosystems
Altis Biosystems United States

Capturing the Complexity of the Human Gut

Series A
28 employees
Biotechnology, Health Care
StemoniX vs
InvivoSciences® Inc.
InvivoSciences® Inc. United States

Discovery with Human touch

Non Equity Assistance
4 employees
Biotechnology, Health Care
StemoniX vs
Qureator
Qureator United States

Create to Cure

Series A
22 employees
Biotechnology, Life Sciences

FAQ About StemoniX

Pre-plated, human iPSC-derived microOrgans for toxicology and drug discovery research
StemoniX was founded in 2014.
StemoniX is headquartered in Maple Grove, United States.
StemoniX operates in the following industries: Biotechnology, Health Care.
StemoniX has approximately 1 employees.
StemoniX has completed 11 funding rounds, raising a total of $33.21M. The latest funding stage is Convertible Note.
Top alternatives and competitors to StemoniX include Altis Biosystems, InvivoSciences® Inc., Qureator , LifeNet Health LifeSciences, AMSBIO. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
StemoniX and Altis Biosystems are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors StemoniX and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works
Bounce Watch

European company intelligence that says when we last looked — so a person can act on it, and so can a machine.

Signals worth an inbox

Funding, hiring, expansion and leadership moves at the companies you track. Written when something happens, not on a schedule.

One click to unsubscribe, in every email. We never share your address.

© 2026 Bounce Watch. All rights reserved. · Based in Amsterdam

GDPR Terms Privacy Your data

One analytics cookie (Google Analytics). Cookie Policy